Elevance Health (NYSE:ELV) Issues Earnings Results, Beats Expectations By $0.04 EPS

Elevance Health (NYSE:ELV) issued its earnings results on Thursday. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.04, Zacks reports. Elevance Health had a net margin of 3.68% and a return on equity of 19.56%. Elevance Health updated its FY 2025 guidance to 34.150-34.850 EPS.

Elevance Health Stock Up 0.0 %

NYSE:ELV opened at $401.43 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.50 and a quick ratio of 1.50. The company’s fifty day moving average price is $386.21 and its 200-day moving average price is $462.34. Elevance Health has a 1-year low of $362.21 and a 1-year high of $567.26. The firm has a market capitalization of $93.10 billion, a P/E ratio of 14.63, a PEG ratio of 1.11 and a beta of 0.84.

Elevance Health Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Monday, March 10th will be paid a dividend of $1.71 per share. This represents a $6.84 annualized dividend and a yield of 1.70%. This is a boost from Elevance Health’s previous quarterly dividend of $1.63. The ex-dividend date of this dividend is Monday, March 10th. Elevance Health’s payout ratio is presently 23.77%.

Analysts Set New Price Targets

Several equities analysts have issued reports on ELV shares. Truist Financial cut their target price on Elevance Health from $520.00 to $480.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. StockNews.com upgraded shares of Elevance Health from a “hold” rating to a “buy” rating in a research note on Friday, January 17th. Mizuho lowered their target price on shares of Elevance Health from $585.00 to $505.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Raymond James set a $485.00 price target on Elevance Health in a research report on Friday, October 18th. Finally, UBS Group lowered their price objective on Elevance Health from $605.00 to $555.00 and set a “buy” rating for the company in a research report on Friday, October 18th. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $525.60.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.